Pipeline

Philochem discovers, patents, and develops an innovative Pipeline of anti-cancer drugs characterized by an exceptional tumor-targeting selectivity.

Target: FAP

Preclinic

Phase I

Phase II

Phase III

Partner

68Ga-OncoFAP – Various Solid Tumors (Imaging)

–

–

–

–

Bracco

18F-OncoFAP –Various Solid Tumors (Imaging)

–

–

–

–

Bracco

177Lu-OncoFAP-23 – Various Solid Tumors (Therapy)

–

–

–

–

–

OncoFAP–GlyPro-MMAE – Various Solid Tumors (Therapy)

–

Animal patients

–

–

–

Target: ACP3

Preclinic

Phase I

Phase II

Phase III

Partner

68Ga-OncoACP3 – Prostate Cancer (Imaging)

–

–

–

–

RayzeBio

18F-OncoACP3 – Prostate Cancer (Imaging)

–

–

–

–

RayzeBio

177Lu-OncoACP3 – Prostate Cancer (Therapy)

–

–

–

–

RayzeBio

225Ac-OncoACP3 – Prostate Cancer (Therapy)

–

–

–

–

RayzeBio

Target: CAIX

Preclinic

Phase I

Phase II

Phase III

68Ga-OncoCAIX – Renal Cell Carcinoma (Imaging)

–

–

–

–

177Lu-OncoCAIX – Renal Cell Carcinoma (Therapy)

–

–

–

–

Philochem builds the chemical pipeline of the Philogen group. For the complete pipeline of the Philogen group see www.philogen.com